Compare Pan American Silver Corp. Common Stock (PAAS) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pan American Silver Corp. Common Stock vs Tango Therapeutics Inc. — how do they compare? Pan American Silver Corp. Common Stock trades at $42.74 (market cap $18.39B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Pan American Silver Corp. Common Stock is far larger — about 4.9× Tango Therapeutics Inc.'s market cap, and Pan American Silver Corp. Common Stock pays a 1.65% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pan American Silver Corp. Common Stock for 2 Days and Tango Therapeutics Inc. for 0 Days on average.
| PAAS | TNGX | |
|---|---|---|
Market Cap | $18.39B | $3.75B |
Volume | 3,168,808 | 9,619,106 |
Sector | Basic Materials | Health |
52-Week High | $68.70 | $32.90 |
52-Week Low | $33.20 | $7.50 |
Typical Hold Time | 2 Days | 0 Days |
Enterprise Value | $17.52B | $2.77B |
Dividend Yield | 1.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pan American Silver (PAAS) trades at $44.53, down 2.58% on the day, with a bearish technical signal from moving averages. The company reported strong 2025 results with $978M net income and a 32.03% net margin, and analysts project 2026 revenue growth to $4.3B. Recent news highlights growth from the Timmins and La Colorada projects and a director retirement effective October 31, 2026.
The outlook is positive with a consensus price target of $62.50, implying 40% upside, supported by solid cash flow and reserve growth. Risks include silver price volatility and potential cost pressures. Analyst sentiment is bullish with 52% buy ratings, but technical indicators suggest near-term caution.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Pan American Silver Corp. Common Stock
Pan American Silver is a mining company focused on silver and gold production in the Americas. It also explores and develops precious metals properties.
Read more on PAAS →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
